NCT06902753Suspended
Adaptation and Normalization of a Verbal Episodic Memory Test in French Sign Language
Adaptation and Normalization of a Verbal Episodic Memory Test (16-item Free and Cued Recall / RL-RI 16) in French Sign Language
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Reason given: Inclusions suspended during the period between phase 1 (adaptation of the test in French sign Language) and phase 2 (inclusion for the standardization of the test).
Brief summary (registry, in English)
To date, neuropsychological assessment of deaf signing persons is complicated by a lack of resources, especially the absence of tools available in French Sign Language (LSF). This is due to perceptual and cultural differences, and in particular the linguistic differences between French and LSF. This lack of resources significantly hinders access to care for deaf patients, as neuropsychological assessment is often a key clinical criterion in the diagnosis of certain neurological pathologies (Alzheimer's disease in particular) and enables coherent care plans to be drawn up, for example in the aftermath of strokes or traumatic brain injuries. In particular, episodic memory (which refers to the ability to memorise information anchored in a specific context) is a cognitive domain that is sensitive to pathologies such as Alzheimer's disease, but it is not currently possible to assess it with deaf signing patients. The aim of this study is to create a memory assessment test adapted to a deaf population that expresses in LSF and to normalize this test on this same population. The aim is to provide a diagnosis assessment tool, which currently does not exist in France, to improve access to care for deaf people. This project could then be extended to the creation of tests for other cognitive domains (executive functions, attention, social cognition, etc.) and to prospects for cognitive remediation. The 16-item Free and Cued Recall test (RL-RI 16) is the best choice because it is easy to use and accurate enough to assess each stage of episodic memory. These qualities make it a decisive tool in certain differential diagnosis.
- Status (registry)
- Suspended
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 30 Dec 2024
- Start date
- 5 May 2025
- Primary completion date
- Nov 2027
- Lead sponsor
- Poitiers University Hospital
- Diseases
- Alzheimer disease
- NCT number
- NCT06902753
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- A score ≤ 20/28 or 17/28 at the MMS-LS test, depending on the schooling of the participant (20/28 for participants with a degree, 17/28 for participants without a degree)
Who the study is looking for
- Person aged ≥ 18 yo
- with severe or profound deafness (hearing loss ≥ 70 decibels), early diagnosed (before 6 years old)
- whose main language is French Sign Language
- able to consent in writing after a clear explanation of the procedure
- affiliated to the French Healthcare system (Sécurité Sociale) through self or another person
- Non-inclusion Criteria:
- person with a medical history in neurology (stroke, traumatic brain injury, dementia) or psychiatry bipolar syndrom or schizophrenia that would not be medicated, severe depression)
- persons with medical developmental backgroung (e.g genetic syndrome)
- person with cancer history needing chemotherapy
- person with a diagnosed and untreated sleeping trouble
- person drinking > 10 glasses of alcohol per week or using drugs on a daily basis
- person with visual issues not corrected
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Poitiers University Hospital | Poitiers | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.